1-3 of 3
Jeroen J. Lammerts van Bueren
Close
Sort by
Journal Articles

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Ida H. Hiemstra, PhD, Patrick J. Engelberts, BS, Bart de Jong, BS, Danita H Schuurhuis, PhD, Theodora W. Salcedo, PhD DABT, Sandra Verploegen, PhD, Marten van der Zee, PhD, Arnout F. Gerritsen, PhD, Nedjad Losic, PhD, Sjeng Horbach, PhD, Roberto Oliveri, MD PhD, Jeroen J. Lammerts van Bueren, PhD, Pernille Autzen Usher, PhD, Janine Schuurman, PhD, Paul W. H. I. Parren, PhD, Esther C. W. Breij, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1664.
https://doi.org/10.1182/blood-2018-99-115957
Published: 2018
Journal Articles

Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking.

J. H. Marco Jansen, Peter Boross, PhD, Marije B. Overdijk, PhD student, Jeroen J. Lammerts van Bueren, PhD, Paul W.H.I. Parren, PhD, Jeanette H. W. Leusen, PhD
Journal: Blood
Blood (2012) 120 (21): 2974.
https://doi.org/10.1182/blood.V120.21.2974.2974
Published: 2012
Journal Articles

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider-Merck, Wim W. K. Bleeker, Michael Dechant, Thomas Beyer, Roland Repp, Patrick H. C. van Berkel, Tom Vink, Jan G. J. van de Winkel, Paul W. H. I. Parren, Thomas Valerius
Journal: Blood
Blood (2008) 112 (6): 2390–2399.
https://doi.org/10.1182/blood-2008-03-144600
Published: 2008
Includes: Supplemental data